Stable Istotope Labelled Navicixizumab Biosimilar – Anti-DLL4 mAb – Research Grade

Reference: PX-TA1026-SIL-1MG
Product nameStable Istotope Labelled Navicixizumab Biosimilar - Anti-DLL4 mAb - Research Grade
SourceIMGT/mAb-DB 597
SpeciesHuman
Expression systemMammalian cells
Molecular weightLC1-2: 24kDa
HC1: 49kDa
HC2: 49kDa
Purity>95%
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsNavicixizumab
ReferencePX-TA1026-SIL
Related ProductsPX-P5121
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG2Kappa (bispecific)
ClonalityMonoclonal Antibody
SourceIMGT/mAb-DB 597
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information about Navicizumab

Navicizumab is a bispecific antibody that target Delta-like ligand 4 (DLL4) as well as vascular endothelial growth factor (VEGF).
DLL4 protein is encoded by DLL4 gene and is part of a signaling pathway known as Notch pathway. This pathway is responsible for the development of many tissues. The attachment of DLL4 protein to its receptor, Notch1, launches a series of signaling reactions that affect different cell functions. Furthermore, DLL4 protein is involved in the development of blood vessels before birth and throughout life. In cancer, the notch induced pathway is essential for tumor angiogenesis and the stemness of cancer cells.
VEGF is a sub-family of growth factors also involved in the formation of blood vessels. Indeed, VEGF is a signaling protein in vasculogenesis and angiogenesis. VEGF is important in restoring the oxygen supply to tissues in hypoxic conditions where blood circulation is scarce. VEGF is also responsible for the establishment of new blood vessels following injury. This protein has also been linked to the formation of new blood vessels throughout the embryonic development. Overexpression of VEGF have been linked to several diseases including cancer. In cancer, VEGF upregulation has been linked to metastasis.
Navicizumab inhibits DLL4/VEGF pathway inducing, as a result, a potent anti-tumor response. Furthermore, this therapeutic antibody can mitigate the toxicities related to angiogenesis. The anti-tumor activity of this therapeutic antibody was demonstrated in phase 1a clinical trials for several cancers including ovarian cancer, fallopian tube cancer, solid tumors and peritoneal cancer. The findings from phase Ia trials suggest that the intake of navicizumab is safe and can be administered on a continuous basis.
As per 2019, navicizumab was granted fast grand designation by U.S food and drug industry (FDA) as a potential treatment for heavily pretreated ovarian cancer. The purpose of this designation is to expedite clinical development and review process and facilitate drug entering the market, This product is for research use only.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Navicixizumab Biosimilar – Anti-DLL4 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.